Literature DB >> 7728476

The prognosis and treatment of true local cutaneous recurrent malignant melanoma.

C D Brown, J A Zitelli.   

Abstract

BACKGROUND: The prognosis and treatment of true local cutaneous recurrent malignant melanoma is presently unknown. We define this entity as melanoma bearing an in situ component that recurs contiguous with the scar of the primary excision. Although previously uncommon, the incidence of true local recurrent melanoma may rise due to the recent use of more narrow margins for excision of thin primary melanoma.
OBJECTIVE: We hypothesized that there is a difference in prognosis between true local cutaneous recurrent melanoma versus local recurrence from satellite or in-transit metastases. Also, we defined guidelines for the surgical management of true local cutaneous recurrent melanoma.
METHODS: We calculated the surgical margin necessary to reach a tumor-free plane using Mohs surgery in 50 patients with true local recurrent melanoma. Patient survival was determined by the Kaplan-Meier method.
RESULTS: Seventy-six percent of the tumors were completely excised using a margin of less than 1 cm. However, a margin of up to 2 cm was required to successfully treat all 50 patients. Thicker tumors did require significantly larger margins. The Kaplan-Meier 5-year overall and melanoma survival rates were 89% and 98%, respectively. The 5-year disease-free survival rate was 66%.
CONCLUSION: The prognosis of true local recurrent melanoma is related to tumor thickness. We recommend full-thickness excision of the entire old scar including a 2-cm margin or Mohs surgery if a narrower margin of resection is desired.

Entities:  

Mesh:

Year:  1995        PMID: 7728476     DOI: 10.1111/j.1524-4725.1995.tb00174.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  8 in total

1.  Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death.

Authors:  Prathamesh M Kulkarni; Eric J Robinson; Jing Wang; Yvonne M Saenger; Jaya Sarin Pradhan; Robyn D Gartrell-Corrado; Bethany R Rohr; Megan H Trager; Larisa J Geskin; Harriet M Kluger; Pok Fai Wong; Balazs Acs; Emanuelle M Rizk; Chen Yang; Manas Mondal; Michael R Moore; Iman Osman; Robert Phelps; Basil A Horst; Zhe S Chen; Tammie Ferringer; David L Rimm
Journal:  Clin Cancer Res       Date:  2019-10-21       Impact factor: 12.531

Review 2.  The changing prognosis of melanoma.

Authors:  A C Buzaid; C M Anderson
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

3.  Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma.

Authors:  Robyn D Gartrell; Douglas K Marks; Emanuelle M Rizk; Margaret Bogardus; Camille L Gérard; Luke W Barker; Yichun Fu; Camden L Esancy; Gen Li; Jiayi Ji; Shumin Rui; Marc S Ernstoff; Bret Taback; Sarabjot Pabla; Rui Chang; Sandra J Lee; John J Krolewski; Carl Morrison; Basil A Horst; Yvonne M Saenger
Journal:  Clin Cancer Res       Date:  2019-01-15       Impact factor: 12.531

Review 4.  [Malignant head and neck melanoma: Part 2: Therapy].

Authors:  C Pföhler; T Vogt; C S L Müller
Journal:  HNO       Date:  2015-08       Impact factor: 1.284

Review 5.  Diagnosis and management of lentigo maligna: a review.

Authors:  Julia M Kasprzak; Yaohui G Xu
Journal:  Drugs Context       Date:  2015-05-29

6.  Achieving Self-Directed Integrated Cancer Aftercare (ASICA) in melanoma: protocol for a randomised patient-focused pilot trial of delivering the ASICA intervention as a means to earlier detection of recurrent and second primary melanoma.

Authors:  P Murchie; J Masthoff; F M Walter; K Rahman; J L Allan; N Burrows; C Proby; A J Lee; M Johnston; A Durrani; I Depasquale; B Brant; A Neilson; F Meredith; S Treweek; S Hall; A McDonald
Journal:  Trials       Date:  2019-06-03       Impact factor: 2.279

7.  The Achieving Self-directed Integrated Cancer Aftercare Intervention for Detection of Recurrent and Second Primary Melanoma in Survivors of Melanoma: Pilot Randomized Controlled Trial.

Authors:  Peter Murchie; Lynda Constable; Susan Hall; William Brant; Julia Allan; Marie Johnston; Judith Masthoff; Amanda Lee; Shaun Treweek; Dolapo Ayansina; Charlotte Proby; Kaz Rahman; Fiona Walter; Nigel Burrows; Amer Durrani; Graeme Maclennan
Journal:  JMIR Cancer       Date:  2022-09-08

8.  [Recurrence of malignant achromic melanoma of the nail: report of a case].

Authors:  Youssef Benyass; Bouchaib Chafry; Kaldadak Koufagued; Salim Bouabid; Driss Benchebba; Belkacem Chagar
Journal:  Pan Afr Med J       Date:  2015-12-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.